Nuclear Medicine and Biology

Nuclear Medicine and Biology began in 1973 as an Elsevier (then Pergamon Press) title and was rebranded in 1985 as Part B of the International Journal of Radiation Applications and Instrumentation before reverting to its current name; it is the official journal of the Society of Radiopharmaceutical Sciences. Its scope is radiopharmaceutical science across the full pipeline: automated and manual radiosynthesis, in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy and translational clinical studies of new targeted radiotracers, with editorial guidance that the importance of the biological target should be the primary justification for publication, ahead of chemistry novelty alone.

It is a natural venue for first-in-human biodistribution and dosimetry papers on new PET/SPECT tracers and for methods papers on radiolabelling chemistry, generator systems and quality control — material that is often too preliminary or too chemistry-focused for the large clinical journals.

Elsevier's ScienceDirect Insights page for the journal states an impact factor of 3.0 and a CiteScore of 6.9; third-party trackers place the equivalent Clarivate JCR value in the range of roughly 2.6-3.0 depending on the release year, so the exact figure should be checked against the current JCR release before being quoted precisely.